Figure 5 | Scientific Reports

Figure 5

From: Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20

Figure 5The alternative text for this image may have been generated using AI.

Production of various antibody forms and their CDC in a rituximab-resistant cell line. (a) Schematic diagrams for the expression of the SBU-CD55 × CD20 and control antibodies (rituximab, IgG-scFv-CD55 × CD20, and scFv-Fc-CD55 × CD20). (b) SDS-PAGE analysis showing the purified SBU-CD55 × CD20 and control antibodies (rituximab, IgG-scFv-CD55 × CD20, and scFv-Fc-CD55 × CD20) in reduced and nonreduced conditions. Lane 1: reduced rituximab; Lane 2: nonreduced rituximab; Lane 3: reduced IgG-scFv-CD55 × CD20; Lane 4: nonreduced IgG-scFv-CD55 × CD20; Lane 5: reduced scFv-Fc-CD55 × CD20; Lane 6: nonreduced scFv-Fc-CD55 × CD20; Lane 7: reduced SBU-CD55 × CD20; Lane 8: nonreduced SBU-CD55 × CD20. (c,d) CDC of SBU-CD55 × CD20 in rituximab-resistant cell lines (Ramos-RR and BJAB). Ramos-RR (c) and BJAB (d) cells were used to measure the CDC of SBU-CD55 × CD20 and three control antibodies (rituximab, IgG-scFv-CD55 × CD20, and scFv-Fc-CD55 × CD20). Error bars represent standard errors calculated from triplicate samples. P-values < 0.05, < 0.01, and > 0.05 are marked with *, **, and “n.s.” for not significant, respectively.

Back to article page